Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Stomach Neoplasms 1Skin Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 6Nivolumab 5cemiplimab 3Photochemotherapy 3Ipilimumab 3Vemurafenib 2Hsp90 inhibitor KU757 2tozuleristide 1toripalimab 1tislelizumab 1spartalizumab 1small molecule inhibitor THX-B 1poly ICLC 1montanide ISA 51 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cobimetinib 1cc-486 1brodalumab 1avelumab 1atezolizumab 1Ultraviolet Rays 1Tumor Necrosis Factor-alpha 1Sunscreening Agents 1Sugars 1SUB1 protein, human 1Radiotherapy 1Propranolol 1Poly I-C 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Skin Neoplasms × Poly I-C × Clear all
NCT00094003 2005-11-11

Study of NS-9 in Patients With Liver Metastases

NS Pharma, Inc.

Phase 1 Completed
20 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡